Kymriah(Tisagenlecleucel) of Novartis Korea, dubbed an ultra-high-priced "one-shot treatment" with a cost of 500 million won per dose, passed the committee. The HIRA (Director Kim Sun-min) held the first Drug Reimbursement Evaluation Committee in 2021 on the afternoon of the 13th and conducted a review on the appropriateness of medical care benefits for five items such as Nasa Care Realtris Nasal Spray 18mL or 31mL.

At that time, the deliberation committee was slightly delayed until the agenda was presented.
▲ Higher levels of risk sharing by pharmaceutical companies considering the level of overseas drug prices, ▲ In the case of diffuse giant B-cell lymphoma, which has insufficient clinical perfo